Göktekin TENEKECİ, Hıdır KILINÇ, Bilge BİLEN TÜRK

Squamous cell carcinoma accompanying chronic myeloid leukemia: Case report and review of the literature

Giriş: Kronik Miyeloid Lösemi (KML), miyeloid hücrelerin aşırı üretimi ile karakterize miyeloproliferatif bir hastalıktır. Hidroksiüre de miyeloproliferatif sendromlarda sıklıkla kullanılan bir antimetabilolit ilaçtır. Hidroksiüre tedavisine bağlı olarak bildirilen cilt değişiklikleri kserozizsten mukokutanöz kanserlere kadar çeşitlilik gösterir. Amaç: Bu çalışmada amacımız, hidroksiüre tedavisi alan hastalarda skuamoz hücreli karsinom gelişiminin altta yatan sebeplerini anlamak, tartışmak ve tümör eksizyonu ve rekonstruksiyonu yaptığımız böyle bir hastayı sunmaktır. Meteryal ve Metod: Üst dudak ve sol el dorsumunda skuamoz hücreli karsinom tanısı almış olan hasta dört yıldır hidroksiüre tedavisi almaktaymış. Bu hasta opere edilerek tümöral kitleleri eksize edildi ve üst dudakta oluşan defekt iç ve alt tarafları greftlenen nazolabial flep ile rekonstrukte edildi. El dorsumunda oluşan defekt ise cilt grefti ile kapatıldı. Bulgular: Yapılan operasyona bağlı bir komplikasyon ile karşılaşılmadı. Postoperatif sekiz aylık takip döneminde hastanın operasyona bağlı bir şikayeti olmadı. Sonuç: Hidroksiüre tedavisi alan hastaların cilt lezyonları cilt kanserine ilerleyebileceğinden dolayı dikkatli bir şekilde muayene edilmeli ve düzenli olarak takip edilmelidir.

Kronik miyeloid lökemi’ye eşlik eden skuamoz hücreli karsinom: Olgu sunumu ve literatür taraması

Background: Chronic Myelogenous Leukemia (CML) is a myeloproliferative disorder characterized by, overproduction of myeloid cells. Hydroxyurea is an antimetabolite which is commonly used in myeloproliferative syndromes. Reported skin changes related to hydroxyurea therapy may range form xerosis to mucocutaneous cancers. Aim: In this study, our aim was to understand and discuss the underlying reason for the development of squamous cell carcinoma (SCC) in patients recieving hydroxyurea and present a case, in whomwe operated to excise the tumoral masses and reconstruct them. Materials and Methods: After recieving hydroxyuea therapy for four years, the patient was diagnosed as squamous cell carcinoma on the upper lip and, on the dorsum of the left hand. She was operated and the tumoral masses were excised. The lesion on the upper lip was reconstructed with nasolabial flap, inner and inferior sides of the flap was skin grafted. The defect on the dorsum of the hand was skin grafted. Results: No complication related to operation occured. Throughout postoperative eight months of follow-up period, the patient had no complaint regarding the operation. Conclusıon: Skin lesions of patients recieving hydroxyurea therapy must be carefully examined and monitored regularly, since these lesions may proceed to skin cancers.

___

1. Bolin RW, Robinson WA, Sutherland J, et al. Busulfan Versus Hydroxyurea in the Long-term Therapy of Chronic Myelogenous Leukemia. Cancer 1982; 50: 1683- 6. DOI: 10.1002/1097-0142(19821101)50:9_____1683::AIDCNCR2820500904> 3.0.CO;2-X
2. Kennedy BS, Smith LR, Goltz RW. Skin Changes Secondary to Hydroxyurea Therapy. Arch Dermatol 1975; 11: 183-7. DOI: 10.1001/archderm.1975.01630140041002
3. Gropper CA, Don PC, Sadjadi MM. Nail and Skin Pigmentation Associated with Hydroxyurea Therapy for Polycythemia Vera. Int J Dermatol 1993; 32: 731-3. DOI: 10.1111/j.1365-4362.1993.tb02745.x
4. Nguyen TV, Margolis DJ. Hydroxyurea and Lower Leg Ulcers. Cutis 1993; 52: 217-9.
5. Sigal M, Crickx B, Blanchet P, et al. Lesions Cutanees Induites par L’utilisation au Long Cours de L’hydroxyurea en Chronic Myelogenous Leukemia. Ann Dermatol Venereol 1984; 111: 895-900.
6. Richard M, Truchetet F, Friedel J, et al. Skin Lesions Simulating Dermatomyositis During Long-term Hydroxyurea Therapy. J Am Acad Dermatol 1989; 21: 797-9. DOI: 10.1016/S0190-9622(89)80274-9
7. Weber LL, Schick E, Merkel M, et al. Dermatomyositis- Like Skin Changes with Long Term Hydroxyurea (Litalir) Therapy. Hautartz 1995; 46: 717-21. DOI: 10.1007/s001050050328
8. Dadoud MS, Gibson LE, Pittelkow MR. Hydroxyurea Induced Dermopathy: A Unique Lichenoid Eruption Complicating Long Term Therapy with Hydroxyurea. J Am Acad Dermatol 1997; 36: 178-82. DOI: 10.1016/S0190-9622(97)70276-7
9. Papi M, Didona B, De Pita O, et al. Multiple Skin Tumors on Light Exposed Areas During Long-term Treatment with Hydroxyurea. J Am Acad Dermatol 1993; 28: 485-6. DOI: 10.1016/S0190-9622(08)81758-6
10. Grange F, Coulliet D, Audhuy B, et al. Keratoses Multiples Induites par L’hydroxyuree. Ann Dermatol Venereol 1995; 122: 16-8.
11. Linker CA. Blood, chronic myelogenous leukemia. In: Tierney LM, McPhee SJ, Papadakis MA, editors. Current Medical Diagnosis and Treatment. 41st ed. Mc Graw Hill; 2002. pp539-41.
12. Albano EA, Stork LC, Greffe BS, Odom LF, Foreman N. Neoplastic disease, chronic myelogenous leukemia. In: Hay WW, Groothuis JR, Hayward AR, Levin MJ, ed(s). Current Pediatric Diagnosis and Treatment. 13th ed. Appleton & Lange; 1997: 785.
13. Yarbro JB. Further Studies on the Mechanism of Action of Hydroxyurea. Cancer Res 1968; 28: 1082-7.
14. Zu-An Y, Xinzhi L, Xianting Z. The Effect of Hydroxyurea on the Expression of the Common Fragile Site 3p14. J Med Genet 1987; 24: 593-6. DOI: 10.1136/jmg.24.10.593
15. Best PJ, Petitt RM. Multiple Skin Cancers Associated with Hydroxyurea Therapy. Mayo Clin Proc 1998; 73: 961-3. DOI: 10.4065/73.10.961
16. Klem EB. Effect of Antipsoriasis Drugs and Metabolic Inhibitors on the Growth of Epidermal Cells in Culture. J Invest Dermatol 1978; 9: 27-32. DOI: 10.1111/1523- 1747.ep12543421
17. Francis AA, Blevins RD, Carrier WL, et al. Inhibition of DNA Repair in Ultraviolet-irradiated Human Cells by Hydroxyurea. Biochem Biophys Acta 1979; 563: 385-92.
18. Angeli-Besson C, Koeppel MC, Jacquet P, et al. Multiple Squamous Cell Carcinomas of the Scalp and Chronic Leukemia. Dermatology 1995; 191: 321-2. DOI: 10.1159/000246586
19. Aste N, Fumo G, Biggio P. Multiple Squamous Epitheliomas During Long-term Treatment with Hydroxyurea. J Eur Acad Dermatol Venerol 2001; 15: 89- 90. DOI: 10.1046/j.1468-3083.2001.00200-11.x
20. Chang WC, Fujimiya Y, Casteel N, Pattengale P. Natural Killer Cell Immunodeficiency in Patient with Chronic Myelogenous Leukemia. Dermatologica 1991; 183: 47-8.
21. Vasallo C, Passamonti F, Merante S, et al. Mucocuataneous Changes During Long-term Therapy with Hydroxyurea in Chronic Myeloid Leukaemia. Clin Exp Dermatol 2001; 26: 141-8. DOI: 10.1046/j.1365- 2230.2001.00782.x
22. Benedittis MDe, Petruzzi M, Giardina C, et al. Oral Squamous Cell Carcinoma During Long-term Treatment with Hydroxyurea. Clinical and Experimental Dermatology 2004; 29: 605-7. DOI: 10.1111/j.1365- 2230.2004.01586.x
23. Esteve E, Georgescu V, Heitzmann P, Martin L. Multiple Skin and Mouth Squamous Cell Carcinomas Relate to Long Term Treatment with Hydroxyurea. Ann Dermatol Venereol 2001; 128: 919-21.
24. Guyatt GH, Sackett DL, Cook DJ. Users’ Guide to the Medical Literature. II. How o Use an Article About Therapy or Prevention. B. What are the Results and will They Help Me in Caring Form My Patients? Evidence- Based Medicine Working Group. JAMA 1994; 271: 59-63. DOI: 10.1001/jama.1994.03510250075039